{"id":"d87539d7846b","type":"article","url":"https://hartvaat.nl/2016/05/03/diabetes-en-preventie-van-laat-myocardinfarct-na-stenting-dapt-studie/","title":"Diabetes en preventie van laat myocardinfarct na stenting: DAPT-studie","title_en":"Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["diabetes-en-hart","diabetes-type-1","diabetes-type-2","dubbele-trombocytenremming","figaro-dkd","obesitas","soul-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.115.016783","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.115.016783","authors":["Ian T Meredith","Jean-François Tanguay","Dean J Kereiakes","Donald E Cutlip","Robert W Yeh","Kirk N Garratt","David P Lee","P Gabriel Steg","W Douglas Weaver","David R Holmes","Ralph G Brindis","Jaroslaw Trebacz","Joseph M Massaro","Wen-Hua Hsieh","Laura Mauri"],"significance":6,"published":"2016-05-03","source_date":"2016-05-03","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This DAPT study analysis showed that continued thienopyridine therapy beyond 12 months after stenting reduces late MI in diabetic patients, identifying diabetes as a modifier of the benefit from extended dual antiplatelet therapy.","created":"2026-07-03T10:26:06Z","updated":"2026-07-03T13:25:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Analyse van de DAPT-studie naar het effect van verlengde duale antiplaatjestherapie op laat myocardinfarct bij diabetespatiënten na coronaire stentplaatsing. Diabetes verhoogt het ischemisch risico en kan de DAPT-duur beïnvloeden.","abstract_original":"BACKGROUND: Patients with diabetes mellitus (DM) are at high risk for recurrent ischemic events after coronary stenting. We assessed the effects of continued thienopyridine among patients with DM participating in the Dual Antiplatelet Therapy (DAPT) Study as a prespecified analysis. METHODS AND RESULTS: After coronary stent placement and 12 months treatment with open-label thienopyridine plus aspirin, 11 648 patients free of ischemic or bleeding events and who were medication compliant were randomly assigned to continued thienopyridine or placebo, in addition to aspirin, for 18 more months. After randomization, patients with DM (n=3391), in comparison with patients without DM (n=8257), had increased composite outcome of death, myocardial infarction (MI), or stroke (6.8% versus 4.3%, P<0.001), increased death (2.5% versus 1.4%, P<0.001), and MI (4.2% versus 2.6%, P<0.001). Among patients with DM, in a comparison of continued thienopyridine versus placebo, rates of stent thrombosis were 0.5% versus 1.1%, P=0.06, and rates of MI were 3.5% versus 4.8%, P=0.058; and among patients without DM the rates were 0.4% versus 1.4%, P<0.001 (stent thrombosis, P interaction=0.21) and 1.6% versus 3.6%, P<0.001 (MI, P interaction=0.02). Bleeding risk with continued thienopyridine was similar among patients with or without DM (interaction P=0.61). CONCLUSIONS: In patients with DM, continued thienopyridine beyond 1 year after coronary stenting is associated with reduced risk of MI, although this benefit is attenuated in comparison with patients without DM. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00977938."}